Ranbaxy forfeits 180 days exclusivity for generic Nexium

January 28, 2015 10:53 AM

14 0

In a fresh setback, Ranbaxy today said US health regulator FDA has determined that the drug maker has forfeited its 180-day exclusivity to sell generic version of digestive disorder medicine Nexium in the American market.

“We have now received a communication from US FDA that they have determined that Ranbaxy has forfeited its 180 days exclusivity for esomeprazole magnesium delayed-release capsules,” the company said in a BSE filing.

Read more

To category page